Does Nivolumab Also Work in Previously Untreated Advanced Melanoma?

A study recently published in the British medical journal found that nivolumab, already known to work in patients resistant to ipilimumab, was also effective as first-line treatment in BRAF-negative advanced melanoma.
Melanoma is a skin cancer that begins in melanocytes, the cells that give skin its color. It is less common than other skin cancers but has a more serious course. Although it accounts for approximately 5% of skin cancers, it is the type associated with the poorest outcomes.
When detected early, melanoma can generally be treated surgically. However, in advanced melanoma that has spread to distant tissues (metastatic melanoma), surgery is not sufficiently effective even when performed, because metastases that cannot be detected by imaging are usually present. Surgery in these patients is generally used to reduce cancer spread or relieve painful symptoms rather than to cure the disease. The main treatments are therefore chemotherapy and/or immunotherapy (biological therapy). Immunotherapy helps the body fight cancer by strengthening the immune system and activating it against cancer cells.
BRAF gene testing is important when choosing a treatment for advanced melanoma, because approximately half of all melanomas have a change (mutation) in this gene. Patients who test positive for a BRAF mutation receive drugs that inhibit its product. Those who test negative frequently receive the immunotherapy drug ipilimumab (Yervoy). Clinical studies have shown that nivolumab (Opdivo) provides substantial benefits in patients resistant to ipilimumab. A study recently published in the British medical journal investigated whether nivolumab could benefit advanced melanoma when chosen as first-line treatment rather than after resistance to ipilimumab develops.
The study divided 418 previously untreated patients with BRAF-negative advanced melanoma into two groups. One received dacarbazine, the conventional chemotherapy drug for melanoma, and the other received nivolumab, with follow-up. The 1-year survival rate was higher in the nivolumab group: 73%, compared with 42% in the dacarbazine group. Time without disease worsening (progression-free survival) was also longer with nivolumab (5 months versus 2 months). Severe side effects were less frequent in patients receiving nivolumab as well.
In conclusion, according to this study, nivolumab, already known to work in patients resistant to ipilimumab, is also effective as first-line treatment in BRAF-negative advanced melanoma. However, several studies directly comparing it with ipilimumab are needed before it can be preferred to, or considered an alternative to, ipilimumab as first-line treatment.
Sources
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.